The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

Yasutoshi Kuboki,Tetsuji Terazawa,Toshiki Masuishi,Masato Nakamura,Jun Watanabe,Hitoshi Ojima,Yudai Shinohara,Masahito Kotaka,Hiroki Hara,Takashi Ohta,Eiji Oki,Yu Sunakawa,Soichiro Ishihara,Hiroya Taniguchi,Takako Eguchi Nakajima,Satoshi Morita,Kuniaki Shirao,Takayuki Yoshino

The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

2021

Yasutoshi Kuboki
Tetsuji Terazawa
Toshiki Masuishi
Masato Nakamura
Jun Watanabe
Hitoshi Ojima
Yudai Shinohara
Masahito Kotaka
Hiroki Hara
Takashi Ohta
Eiji Oki
Yu Sunakawa
Soichiro Ishihara
Hiroya Taniguchi
Takako Eguchi Nakajima
Satoshi Morita
Kuniaki Shirao
Takayuki Yoshino

3507Background: The efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) as a later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated in clinical trials. T...

Keywords:

Medicine
Trifluridine
Internal medicine
Oncology
Colorectal cancer
in patient
Bevacizumab
Clinical trial
Irinotecan
second line treatment
Tipiracil

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations